In a regulatory filing, Humana disclosed that members of the company’s senior management team are scheduled to meet with investors and analysts at industry conferences and various other meetings between September 6 and September 30. “During these conferences and meetings, the company intends to reaffirm its guidance of at least $26.91 in diluted earnings per common share or at least $28.25 in adjusted earnings per common share, in each case for the year ending December 31, 2023, or FY23. This guidance is consistent with the guidance issued in Humana’s press release dated August 2,” the filing stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HUM:
- Humana sues U.S. government to block Medicare audit rule
- Humana sues U.S. to block Medicare audit rule, Bloomberg reports
- Humana price target lowered to $624 from $637 at Morgan Stanley
- Alignment Healthcare price target lowered to $12 from $19 at Morgan Stanley
- Jefferies healthcare analysts to hold an analyst/industry conference call